ACE2 and infection: To further explore the antiviral efficacy of tubercidin (Schultz et al, 2022), we pretreated A549‐ACE2 cells with tubercidin at a range of concentrations 3 h prior to infection with SARS‐CoV‐2 and quantified SARS‐CoV‐2 nucleoprotein (N) accumulation by Western blot and immunostaining.